Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Aug;24(8):1232-1233.
doi: 10.1038/s41590-023-01567-1.

A GPCR checkpoint drives CD8+ T cell dysfunction and immunotherapy failure in mice

No authors listed
Comment

A GPCR checkpoint drives CD8+ T cell dysfunction and immunotherapy failure in mice

No authors listed. Nat Immunol. 2023 Aug.
No abstract available

PubMed Disclaimer

Comment on

  • The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.
    Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppin E, Mesirov JP, Gutkind JS. Wu VH, et al. Nat Immunol. 2023 Aug;24(8):1318-1330. doi: 10.1038/s41590-023-01529-7. Epub 2023 Jun 12. Nat Immunol. 2023. PMID: 37308665 Free PMC article.

References

    1. Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, e192535 (2019). An article that examines the responses of patients with cancer to checkpoint inhibitor immunotherapies in the USA - DOI - PubMed - PMC
    1. Wu, V. et al. Illuminating the Onco-GPCRome: novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. J. Biol. Chem. 294, 11062–11086 (2019). A computational analysis highlighting the widespread GPCR–G-protein alterations in tumor biology, and opportunities for new drug targets in cancer immunotherapy. - DOI - PubMed - PMC
    1. Inoue, A. et al. Illuminating G-protein-coupling selectivity of GPCRs. Cell 177, 1933–1947 e1925 (2019). A study that systematically examines ligand-induced interactions between GPCRs and distinct G-protein subunits and the use of machine learning approaches to predict GPCR–G-protein coupling specificity. - DOI - PubMed - PMC
    1. Urban, D. J. & Roth, B. L. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu. Rev. Pharmacol. Toxicol. 55, 399–417 (2015). A review article that presents advances in the use of chemogenetic approaches to investigate the role of GPCRs in physiology, disease and translational settings. - DOI - PubMed
    1. Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017). A study that identifies an immune-related gene expression profile involving the CXCR3–CXCL9, CXCR3–CXCL10 and CXCR3–CXCL11 axes that correlates with clinical responses to anti-PD1 immunotherapy. - DOI - PubMed - PMC

Substances

LinkOut - more resources